SCHEMBL26656332

SCHEMBL26656332

CC1CC(=O)c2cc(Br)ccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.54
EDNRB P24530 2/20 0.44
EDNRA P25101 2/20 0.44
MAPK1 P28482 2/20 0.42
CYP1A2 P05177 1/20 0.42
AR P10275 2/20 0.41
S100A4 P26447 1/20 0.41
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
PTPRC P08575 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
CYP19A1 P11511 1/20 0.36
METAP1 P53582 1/20 0.36
LMNA P02545 1/20 0.35
ESR1 P03372 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14169119 1.00 PBRM1 (0.54) PBRM1EDNRBEDNRAMAPK1CYP1A2
SCHEMBL4419838 0.85 PBRM1 (0.50) PBRM1EDNRBEDNRAMAPK1CYP1A2
SCHEMBL30917701 0.82 PBRM1 (0.44) PBRM1EDNRBEDNRAMAPK1CYP1A2
SCHEMBL8617679 0.82 PBRM1 (0.44) PBRM1EDNRBEDNRAMAPK1CYP1A2
SCHEMBL30917697 0.82 PBRM1 (0.44) PBRM1EDNRBEDNRAMAPK1CYP1A2
SCHEMBL31650648 0.82 PBRM1 (0.44) PBRM1EDNRBEDNRAMAPK1CYP1A2
SCHEMBL29123070 0.79 PBRM1 (0.47) PBRM1EDNRBEDNRAMAPK1CYP1A2
SCHEMBL31371537 0.78 PBRM1 (0.46) PBRM1EDNRBEDNRAMAPK1CYP1A2
SCHEMBL17460769 0.78 CA12 (0.44) MAPK1S100A4CA1CA2HTR2A
SCHEMBL7566810 0.78 ACHE (0.54) CA1CA2HTR2AHTR2CCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522582-B2 Antiviral indolinyl compounds and uses thereof GILEAD SCIENCES, INC. (US) 2026-01-13 US disclosed
EP-4622716-A1 SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS Treeline Biosciences, Inc. (US) 2025-10-01 EP disclosed
EP-4526289-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-03-26 EP disclosed
CN-119546574-A Antiviral indolinyl compounds and uses thereof 吉利德科学公司 2025-02-28 CN disclosed
WO-2024112654-A1 SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS Treeline Biosciences, Inc. (US) 2024-05-30 WO disclosed
US-20240101529-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2024-03-28 US disclosed
WO-2023225162-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-11-23 WO disclosed
WO-2023225162-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101529-A1 ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF MAVS, IRF3, EIF2AK2 PBRM1 1697/4885EDNRB 3594/4885EDNRA 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.